Ms. Michelle Seltenrich reports

RAKOVINA THERAPEUTICS ANNOUNCES UPCOMING WEBINAR WITH VARIATIONAL AI

Rakovina Therapeutics Inc. will host a 60-minute webinar on Dec. 17, 2025, at 10 a.m. PT.

The session, titled From Handshake to Breakthrough, will bring together leaders from Rakovina Therapeutics and Variational AI for a fireside discussion on how the two companies are tackling one of oncology's toughest design challenges: creating CNS-penetrant, multitarget cancer therapeutics. Using the AI-designed ATR/mTOR inhibitor program as a case study, the teams will outline how the partnership began, the biological hurdles they set out to overcome and what the latest preclinical data mean for future development.

The webinar will conclude with an open Q&A (question and answer), allowing participants to engage directly with both organizations.

About Rakovina Therapeutics Inc.

Rakovina Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. The company's work is based on unique technologies for targeting the DNA-damage response powered by artificial intelligence (AI) using the proprietary Deep-Docking and Enki platforms. By using AI, the company can review and optimize drug candidates at a much greater pace than ever before.

The company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners.

We seek Safe Harbor.